CRISPR Custom Targeted Lentiviral sgRNA Library
Studying a large family of genes, or a complex pathway? Now you can knock out, activate, or repress up to 100 target genes with a single custom targeted sgRNA lentiviral pool. Our targeted lentiviral sgRNA library provides you with both a 100 μg pool of 300 different sgRNA plasmids (i.e. 3 gRNA for each target gene to ensure effective targeting) and 1 ml of ≥1 x 107 IU/mL pooled lentiviruses.
Just send your gene list (with species, gene names, and accession numbers) in Microsoft Excel file format to quotes@abmgood.com, and tell us what you plan to do:
- Gene knockouts with any Cas9 Nuclease (check out abm’s Cas9 Expressing Stable Cell Lines)
- Promoter activation with dCas9-SAM
- Promoter repression with dCas9-KRAB
We’ll do the sgRNA design, cloning, and lentiviral packaging for you!
Please visit the CRISPR homepage for more information about genome editing with sgRNA.
Testimonial:
“Construct works beautifully, definitely will get more if needed.”
Emily Chen, UCLA, CRISPR Constructs
Additional Resources:
Additional Info
| Species | sgRNAs can be designed for Human, Mouse or Rat. For all other species, please inquire. |
| Vector | pLenti-U6-sgRNA-PGK-Neo |
| Bacterial Selection | Ampicillin |
| Format | Plasmid and virus |
| Appearance | Liquid |
| Storage | -80°C or below |
| Shelf Life | 1 year (when at -80°C or below in a non-frost free freezer) |
| Shipping | Shipped on Dry Ice |
| Quality Control | Restriction Enzyme Digest and Sequencing |
| Notes | This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. |
Lentiviruses can infect both dividing and non-dividing cells in vitro and in vivo, and will integrate stably into the host cell genome, ensuring long-term expression of the construct even in cells that are difficult to infect. Lentivectors, on the other hand, allow transient expression and can be diluted out.
We can design sgRNAs for gene knockouts with spCas9 Nuclease, for promoter activation with dCas9-SAM, for promoter repression with dCas9-KRAB, or for transgenic knockins of Custom HDR Templates.
Related Products
FAQs
If I place an order for 100 target genes, what are the deliverables?
We will deliver 1 vial of ~100 ug plasmids, which is a pool of 300 sgRNA plasmids targeting 100 genes (i.e. 3 sgRNAs for each target gene), and 1 ml of packaged virus at >1 x 107 IU/ml titre. The deliverables will not be individual tubes of sgRNAs. It will be a single pool of all the sgRNA constructs.
What is the lead time?
The lead time is around 4-6 weeks.
Is Cas9 included in the package?
No, this can be ordered separately. We recommend co-transfection with Cas9 Nuclease NLS Protein (Cat. No. K030 or K130) due to the number of sgRNA constructs included in the pool.
How many vials of Cas9 Nuclease will be required?
The sgRNA plasmids will be supplied as a pool of lentiviral vectors, and a single vial of at least 1 mL of packaged virus will be supplied. Only a single tube of Cas9 Nuclease Lentiviral Vector (Cat. No. K002) is required as it can be amplified by transforming into E. coli and isolating the DNA. If Cas9 Nuclease Lentivirus (Cat. No. K003) is ordered, the amount required will depend on how many different samples the end user is interested in infecting. If you are only working with a few cell ines, then 1 vial may be sufficient to infect the cell to generate stable cell lines expressing Cas9 Nuclease for use with the pool. If you are working with more cell lines, then more than 1 vial may be required.
What species is this service valid for?
Human, mouse or rat. For other species, please inquire.
Citations
| 01 |
Kang, Y. J. et al. “Regulation of NKT cell-mediated immune responses to tumours and liver inflammation by mitochondrial PGAM5-Drp1 signalling.” Nat. Commun. (2015) 6:8371 doi: 10.1038/ncomms9371
|
| 02 |
Jiang, G. et al. “Isorhapontigenin (ISO) inhibits invasive bladder cancer (BC) formation in vivo and human BC invasion in vitro by targeting STAT1/FOXO1 Axis.” Cancer Prev Res. Published Online First April 14, 2016.doi: 10.1158/1940-6207.CAPR-15-0338
|
| 03 | Okugawa, Y. et al. “Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer.” Gut (2015)doi:10.1136/gutjnl-2015-309359 |
